Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Confusion Persists Around the Interchangeability Designation for Biosimilars

November 23rd 2023

By Gillian Woollett, MA, DPhil

The legal and common uses of “interchangeability” continue to be conflated.

Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar

November 22nd 2023

By Skylar Jeremias

Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).

Evolution of Auto-Substitution in Biosimilar Landscape

November 21st 2023

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Defining Interchangeability and Switching in Biologics

November 21st 2023

Medical experts discuss interchangeability designation requirements for biosimilars.

Study Confirms Safety and Efficacy of Adalimumab Biosimilar HS016 in IBD

November 21st 2023

By Cameron Santoro

A China-based study where data were collected from patients with inflammatory bowel disease (IBD) showed safety and efficacy of the adalimumab biosimilar HS016.

BioRationality: FDA Publishes Results of First Meta-Analysis to Conclude All Biosimilars Are Interchangeable

November 20th 2023

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, offers hope for the end of interchangeability labels in the United States in his latest column.

Global Biosimilars Week: Dr Fran Gregory Explores the Growing Oncology Biosimilar Space, Previews Future

November 19th 2023

By Skylar Jeremias

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, examines the evolution of the oncology biosimilar space in this special episode of Not So Different to close out Global Biosimilars Week 2023.

Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone

November 18th 2023

By Deana Ferreri, PhD

A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.

The Top 5 Biosimilar Articles for the Week of November 13

November 17th 2023

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of November 13, 2023.

Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?

November 16th 2023

In partnership with The Center for Biosimilars®, the International Generic and Biosimilar Association hosted a live webinar, where panelists gathered from around the globe to discuss benefits as well as major barriers and accessibility challenges associated with oncology biosimilars worldwide.